Highlights Coronavirus triggered pulmonary and systemic disease has an unpredictable clinical course in different subsets of patients led us to go through literature in a hope that we might contribute to this worldwide fight. COX2, p38 MAPK, IL-1b, IL-6 and TGF-b are playing pivotal roles in coronavirus related cell death, cytokine storm and pulmonary interstitial fibrosis. Still ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition directed us to search the related literature to point out a potential target (COX2) and a weapon (celecoxib).

No abstract

ProblemObjective studies that use validated questionnaires are needed to evaluate the changes in the sexual functions of women diagnosed with human papillomavirus (HPV) infection.Method of StudyThe study comprised 80 sexually active women diagnosed with a high‐risk HPV infection. These patients were divided into four groups as follows: group 1, HPV 16/18‐positive and normal cytology; group 2, HPV 16/18‐positive and abnormal cytology; group 3, non‐16/18 HPV‐positive and abnormal cytology; and group 4, non‐16/18 HPV‐positive and normal cytology. The sexual functions and anxiety statuses of the patients were assessed via the Female Sexual Function Index (FSFI) and Beck anxiety inventory (BAI) questionnaires, respectively, at their first clinical visits and then 2 months later.ResultsThere was no statistically significant difference among the study groups in terms of the overall FSFI and domain sub‐scores at either of the visits. Women who tested positive for the high‐risk HPV 16/18 strains had a significantly less sexual desire after being informed about the test results. Those with HPV 16/18 and normal cytology had significantly higher anxiety levels at their second than first visits. The BAI scores of the HPV 16/18‐positive women (normal or abnormal cytology) at the second visit were significantly higher than those of non‐16/18 HPV‐positive women with normal cytology. There was no significant difference between the patients with normal and abnormal cytology results regarding the difference of BAI, overall and domain FSFI sub‐scores at the first and second visits. The desire and lubrication domain scores of the HPV 16/18‐positive patients significantly decreased after the first visit compared with those of the non‐16/18 HPV‐positive patients.ConclusionHPV 16/18 positivity decreases women's total FSFI and desire domain sub‐scores.

No abstract

No abstract

Antimicrobial prophylaxis has an important role in reducing surgical wound infection rates. Besides prophylaxis; basic infection control mechanisms implemented in the clinic (17), the surgeon's experience and technique, duration of operation, hospital and operating room conditions, instrumentation, preoperative preparation including body-washing, skin antisepsis and shaving, peri-operative management of temperature and blood glucose regulation, and the patient's existing co-morbidities all play an important role (16,18). Patient-related risk factors for surgical wound infections are advanced age, negative nutritional status, obesity, diabetes mellitus, cigarette smoking, presence of infection, immunodeficiency or immunosuppressive use, steroid use, recent surgery, long preoperative hospitalization and colonization with microorganisms. MicroorganismsIn breast and plastic surgery procedures, usually S. aureus is responsible for the wound infection (2,6,7,10,11,15,19,20). In axillary region procedures, obese patients prone to maceration, procedures at sweating areas P. aeruginosa, Serratia marcescens, Enterobacteriaceae including E. coli and gram-negatives like Klebsiella can be isolated (20, 21). . Pages 582-667 of this book contain the section:"Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery". This section includes current clinical developments, evidence and recommendations on the application of standard and effective antimicrobial prophylaxis in adult and pediatric patients, and has significant differences compared to the previous 1999 edition. On pages 632-633, antimicrobial prophylaxis in breast and plastic surgery practice is addressed in detail. This article contains a summary of the recommendations made in ASHP 2012/2013 Report regarding the antimicrobial prophylaxis in breast and plastic surgery applications.

No abstract

No abstract